Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (1145)	4/7/2006 10:03:36 AM
From: zeta1961	Read Replies (1) \| Respond to of 1840

Bristol Sprycel For Gleevec-Resistant Leukemia To Get Committee Review At June ASCO Meeting FDA will take its Oncologic Drugs Advisory Committee on the road to review Bristol-Myers Squibb’s Sprycel (dasatinib) for the treatment of resistant leukemias. The meeting will take place on June 2 in Atlanta, Ga. on the first day of the American Society for Clinical Oncology annual meeting. The ASCO meeting runs June 2-6. Many of the committee members and FDA oncology reviewers regularly attend the meeting, as do Bristol representatives. FDA will give the committee members a break, as they are likely to have time constraints during the ASCO meeting; the agency is only dedicating a half-day to the review, from 10 a.m. to 2 p.m. Bristol is seeking accelerated approval for dasatinib for the “treatment of adults with chronic, accelerated, or blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy, including imatinib” (Novartis’ Gleevec). The company is also seeking an indication for “treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia, and lymphoid blast chronic myeloid leukemia with resistance or intolerance to prior therapy.” Bristol submitted the NDA for Sprycel on Dec. 28. FDA is giving the application a priority review, which would give the product a June 28. user fee deadline. The submission is primarily based on Phase II data from 1,000 Gleevec-resistant or intolerant patient with CML in various phases of disease. According to data presented at the American Society for Hematology in December, 32% of the 74 patients with myeloid blast phase had a major hematologic response with dasatinib and 24% of patients experienced a complete hematologic response. In 107 accelerated phase patients, dasatinib showed a 59% major hematologic response rate with 33% of patients experiencing a complete hematologic response. The response was even higher in chronic phase patients who were intolerant or resistant to Gleevec. Among 59 intolerant patients, 97% had a complete hematologic response. The response rate for 127 resistant chronic phase patients was 87%. Complete cytogenetic response rates for the myeloid blast and accelerated phase patients were in the 30% range, while 22% of chronic phase patients resistant to imatinib had a complete cytogenetic response; 56% of intolerant chronic phase patients had a complete cytogenetic response. The advisory committee will have to determine if the Phase II data on hematologic and cytogenetic responses are enough to predict a clinical benefit for dasatinib, such as prolonged survival in CML patients. Bristol estimates that 15%-20% of patients treated for CML do not achieve major cytogenetic responses to Gleevec within the first 12 months and 5%-10% develop resistance. Dasatinib is an oral multi-target kinase inhibitor, which, Bristol reports, has a pre-clinical potency greater than imatinib. To arrange for a webcast of this meeting, live videoconferencing, or to order videotapes & DVDs, email FDATV@elsevier.com or call 800-627-8171. Posted: Thursday, April 06, 2006 fdaadvisorycommittee.com